Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how well secukinumab works for painful skin condition in daily life

NCT ID NCT06517732

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 107 adults in Russia with moderate to severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) who are taking secukinumab as part of their normal care. Researchers will track how many patients see a 55% reduction in disease severity over time, using a standard scoring system. The goal is to see how well the drug works in real-world settings, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
secukinumab
What this could lead to
If successful, this study could confirm that secukinumab works well in everyday practice for people with hidradenitis suppurativa, supporting its wider use.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes patients already prescribed the drug, and the sample size is small (107 people).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIDRADENITIS SUPPURATIVA

Contacts and locations

Locations

  • Novartis Investigative Site

    Izhevsk, 426039, Russia

  • Novartis Investigative Site

    Kaliningrad, 236016, Russia

  • Novartis Investigative Site

    Kaliningrad, 236029, Russia

  • Novartis Investigative Site

    Kazan', 420012, Russia

  • Novartis Investigative Site

    Kemerovo, 650025, Russia

  • Novartis Investigative Site

    Krasnodar, 350020, Russia

  • Novartis Investigative Site

    Moscow, 107076, Russia

  • Novartis Investigative Site

    Moscow, 119881, Russia

  • Novartis Investigative Site

    Moscow, 123182, Russia

  • Novartis Investigative Site

    Moscow, 129110, Russia

  • Novartis Investigative Site

    Nizhny Novgorod, 603950, Russia

  • Novartis Investigative Site

    Penza, 440052, Russia

  • Novartis Investigative Site

    Saint Petersburg, 197022, Russia

  • Novartis Investigative Site

    Samara, 443079, Russia

  • Novartis Investigative Site

    Saratov, 410028, Russia

  • Novartis Investigative Site

    Stavropol, 355020, Russia

  • Novartis Investigative Site

    Tula, 300053, Russia

  • Novartis Investigative Site

    Ufa, 450010, Russia

  • Novartis Investigative Site

    Yakutsk, 677000, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.